Menconi Francesca, Marinò Michele, Pinchera Aldo, Rocchi Roberto, Mazzi Barbara, Nardi Marco, Bartalena Luigi, Marcocci Claudio
Department of Endocrinology, University of Pisa, Via Paradisa 2, 56100 Pisa, Italy.
J Clin Endocrinol Metab. 2007 May;92(5):1653-8. doi: 10.1210/jc.2006-1800. Epub 2007 Feb 13.
Graves' orbitopathy (GO) is probably caused by autoimmune reactions against autoantigen(s) shared by thyroid and orbital tissues sustained by intrathyroidal autoreactive T-lymphocytes infiltrating the orbit. Total thyroid ablation (TTA) may be beneficial for GO through removal of shared antigen(s) and autoreactive T-lymphocytes, but randomized studies are lacking.
Our objective was to evaluate the effects of TTA in patients with GO treated with iv glucocorticoids (GC).
DESIGN/SETTING: A prospective, single-blind, randomized study was conducted at a referral center.
PATIENTS/INTERVENTIONS: Sixty patients with mild to moderate GO were randomized into: 1) near-total thyroidectomy (TX); or 2) TX plus (131)I (TTA) groups, and then treated with iv GC. Patients were evaluated 3 and 9 months after iv GC.
Overall improvement of GO at 9 months was the main outcome measure.
The distribution of GO outcome at 9 months was significantly more favorable in TTA than in TX patients (P = 0.0014 by chi(2) test). A cumulative significant (P = 0.0054) difference between the two groups at 3 and 9 months was found using a generalized linear model. Radioiodine uptake test and thyroglobulin assay in a patient sample showed complete ablation in the majority of TTA, but not of TX patients.
Compared with thyroidectomy alone, TTA is followed by a better outcome of GO in patients given iv GC. Whether TTA maintains this advantage in the long-term remains to be established.
格雷夫斯眼眶病(GO)可能是由针对甲状腺和眼眶组织共有的自身抗原的自身免疫反应引起的,这种反应由浸润眼眶的甲状腺内自身反应性T淋巴细胞维持。全甲状腺切除(TTA)可能通过去除共有抗原和自身反应性T淋巴细胞而对GO有益,但缺乏随机研究。
我们的目的是评估TTA对接受静脉注射糖皮质激素(GC)治疗的GO患者的影响。
设计/地点:在一个转诊中心进行了一项前瞻性、单盲、随机研究。
患者/干预措施:60例轻至中度GO患者被随机分为:1)近全甲状腺切除术(TX)组;或2)TX加(131)I(TTA)组,然后接受静脉注射GC治疗。在静脉注射GC后3个月和9个月对患者进行评估。
9个月时GO的总体改善情况是主要观察指标。
9个月时GO的结局分布在TTA组比TX组明显更有利(χ²检验,P = 0.0014)。使用广义线性模型发现两组在3个月和9个月时存在累积显著差异(P = 0.0054)。对患者样本进行的放射性碘摄取试验和甲状腺球蛋白测定显示,大多数TTA患者实现了完全消融,而TX患者未实现。
与单纯甲状腺切除术相比,接受静脉注射GC的患者进行TTA后GO的结局更好。TTA在长期是否保持这一优势仍有待确定。